SYMPHONY-1: a phase 1b/3 double-blind, randomised study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma

This trial is testing a treatment combination in people with follicular lymphoma that has either relapsed or come back after treatment.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04224493

Trial aim and background

This is a randomised, double-blind phase 3 trial which aims to evaluate the efficacy and safety of tazemetostat in combination with lenalidomide and rituximab in adults with relapsed or refractory follicular lymphoma.

Your previous treatment has to have been either systemic (whole body) chemotherapy, immunotherapy or chemoimmunotherapy.

Who can enter

Adults with follicular lymphoma which has returned after (relapsed) or not responded to (refractory) at least one systemic treatment.

Locations

Beatson West of Scotland Cancer Centre, Glasgow
Western General Hospital - Haematology, Edinburgh
Imperial College Healthcare NHS Trust - Hammersmith Hospital, London
St Bartholomew's Hospital Barts Health NHS Trust, London

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT04224493

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.